[1]秦佳睿,郑艳莉.子宫内膜癌组织中SCGB2A2表达与上皮-间质转化的关系及对淋巴结转移预测价值的研究[J].现代检验医学杂志,2026,41(02):77-82.[doi:10.3969/j.issn.1671-7414.2026.02.013]
　QIN Jiarui,ZHENG Yanli.The Relationship between SCGB2A2 Expression and Epithelial-Mesenchymal Transformation in Endometrial Carcinoma Tissues and Its Predictive Value for Lymph Node Metastasis[J].Journal of Modern Laboratory Medicine,2026,41(02):77-82.[doi:10.3969/j.issn.1671-7414.2026.02.013]
点击复制

子宫内膜癌组织中SCGB2A2表达与上皮-间质转化的关系及对淋巴结转移预测价值的研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第41卷
期数:
2026年02期
页码:
77-82
栏目:
论著
出版日期:
2026-03-15

文章信息/Info

Title:
The Relationship between SCGB2A2 Expression and Epithelial-Mesenchymal Transformation in Endometrial Carcinoma Tissues and Its Predictive Value for Lymph Node Metastasis
文章编号:
1671-7414（2026）02-077-06
作者:
秦佳睿，郑艳莉
南通市第一人民医院/南通大学第二附属医院，江苏南通 226000
Author(s):
QIN Jiarui，ZHENG Yanli
the First People’s Hospital of Nantong / the Second Affiliated Hospital of Nantong University, Jiangsu Nantong 226000, China
关键词:
子宫内膜癌; 分泌球蛋白家族2A成员2; 上皮-间质转化; 淋巴结转移
分类号:
R737.33；R730.43
DOI:
10.3969/j.issn.1671-7414.2026.02.013
文献标志码:
A
摘要:
目的?探讨子宫内膜癌(EC)组织中分泌球蛋白家族2A成员2(SCGB2A2)表达与上皮-间质转化(EMT)的关系及对淋巴结转移的预测。方法回顾性分析2021年5月~2023年6月南通市第一人民医院妇产科收治的180例EC患者为研究对象,根据淋巴结是否转移分为淋巴结转移组(n=48)和无转移组(n=132)。收集患者的分期、分化、浸润深度、肿瘤直径等临床病理特征,利用蛋白印迹法(Westernblotting)测定SCGB2A2、波形蛋白(Vimentin)、细胞角蛋白19(CK19)和N-钙黏蛋白(N-cadherin),分析EMT相关标志物水平对SCGB2A2与淋巴结转移的中介作用。结果分期Ⅲ~Ⅳ(1.09±0.25)、低分化程度(1.32±0.36)、浸润深度≥1/2(1.34±0.33)、肿瘤直径≥2mm(1.23±0.34)的SCGB2A2表达水平高于分期I~Ⅱ(0.61±0.14)、高分化程度(0.71±0.21)、浸润深度<1/2(0.74±0.23)、肿瘤直径<2mm(0.61±0.18),差异具有统计学意义(t=14.362~16.426,均P<0.001)。淋巴结转移组患者分期为Ⅲ~Ⅳ期(100%)、低分化(56.25%)、浸润深度≥1/2(75%)、肿瘤直径≥2mm(62.50%)的占比高于无转移组(5.30%、31.82%、16.67%、16.67%),差异具有统计学意义(χ2=8.888~148.760,均P<0.05)。淋巴结转移组患者的SCGB2A2(1.03±0.12)、Vimentin(147.56±17.56)、CK19(99.24±14.69),N-cadherin(142.64±15.21)的表达水平高于无转移组患者(0.49±0.08、118.09±16.85、73.58±13.97、121.36±13.84),差异具有统计学意义(t=8.882~34.725,均P<0.001)。SCGB2A2、Vimentin、CK19、N-cadherin是预测淋巴结转移的独立危险因素(OR=1.457~2.825,均P<0.05)。Vimentin、CK19、N-cadherin在SCGB2A2与淋巴结转移中的中介效应分别为0.073、0.087、0.067,差异具有统计学意义(z=3.872、4.411、3.658,均P<0.001)。SCGB2A2与EC患者淋巴结转移风险大致呈显著的正相关,特别当SCGB2A2>0.75时,随着SCGB2A2升高,EC患者淋巴结转移的风险显著上升。结论EMT相关标志物Vimentin、CK19、N-cadherin在SCGB2A2与淋巴结转移之间发挥中介效应,未来治疗中可以通过靶向这些EMT标志物和SCGB2A2来抑制肿瘤转移。
Abstract:
Objective To investigate the relationship between the expression of secretoglobin family 2A member 2 (SCGB2A2) and epithelial-mesenchymal transition (EMT) in endometrial carcinoma (EC), as well as its predictive value for lymph node metas-tasis. Methods A total of 180 EC patients admitted to the Department of Obstetrics and Gynecology, Nantong First People's Hospi-tal from May 2021 to June 2023 were retrospectively selected as the study objects, and were divided into a lymph node metastasis group (n=48) and a non-metastasis group (n=132) based on lymph node metastasis status. Clinicopathological features such as stage, differentiation, depth of invasion and tumor diameter were collected. Western blotting was used to measure the protein levels of SCGB2A2, Vimentin, cytokeratin 19 (CK19) and N-cadherin. The mediating effect of EMT-related markers on the association between SCGB2A2 and lymph node metastasis was analyzed. Result The expression level of SCGB2A2 in stage Ⅲ~Ⅳ(1.09±0.25), poorly differentiated tumors (1.32±0.36), invasion depth ≥1/2 (1.34±0.33), tumor diameter ≥2mm (1.23±0.34) was higher than that in stage I~Ⅱ (0.61±0.14), well-differentiated tumors (0.71±0.21), invasion depth < 1/2 (0.74±0.23), and tu-mor diameter < 2mm (0.61±0.18), with statistically significant differences(t=14.362~16.426, all P<0.001). Patients in the lymph node metastasis group showed higher proportions of stage Ⅲ and Ⅳ (100%), poorly differentiated (56.25%), invasion depth≥1/2 (75%) and tumor diameter≥2mm (62.50%) compared to the non-metastatic group (5.30%, 31.82%, 16.67%, 16.678%), with statistically significant differences (χ2=8.888~148.760, all P<0.05). The expression levels of SCGB2A2 (1.03±0.12), Vimen-tin (147.56±17.56), CK19 (99.24±14.69), N-cadherin (142.64±15.21) in the lymph node metastasis group were higher than the non-metastatic group (0.49±0.08, 118.09±16.85, 73.58±13.97, 121.36±13.84), with statistically significant differences (t=8.882~34.725, all P<0.001). SCGB2A2, Vimentin, CK19, N-cadherin were independent risk factors for predicting lymph node metastasis (OR=1.457~2.852, all P<0.05). The mediating effects of Vimentin, CK19 and N-cadherin in the relationship between SCGB2A2 and lymph node metastasis were 0.073, 0.087, 0.067, respectively, with statistically significant differences (z=3.872, 4.411, 3.658, all P<0.001). SCGB2A2 showed a significant positive correlation with lymph node metastasis in EC patients, espe-cially when SCGB2A2>0.75, as SCGB2A2 increased, the risk of lymph node metastasis in EC patients increased significantly. Conclusions EMT-related markers including Vimentin, CK19 and N-cadherin mediate the association between SCGB2A2 and lymph node metastasis. Future therapeutic strategies targeting these EMT markers and SCGB2A2 may inhibit tumor metastasis.

参考文献/References:

[1] TIAN W J, REN Y L, LU J, et al. Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a sin-gle-arm phase II trial [J]. BMC Medicine, 2024, 22(1): 344.
[2] 夏玲芳,朱俊,吴小华.2023年ESMO妇科肿瘤治疗最新进展及展望[J].中国癌症杂志,2023,33(11):969-980. XIA L F, ZHU J, WU X H. The latest progress and prospect of gynecological tumor treatment at 2023 ES-MO[J]. China Oncology, 2023, 33(11): 969-980.
[3] 李青山,郭红生,贾天阳.ISLR通过活化PI3K-AKT通路促进上皮-间质转化影响骨肉瘤细胞恶性进展研究[J].现代检验医学杂志, 2024, 39(5): 17-21,29. LI Q S, GUO H S, JIA T Y. ISLR promotes epithelial-mesen-chymal transition through activating PI3K-AKT pathway and influences the malignant progression of osteosarcoma cells[J]. Journal of Modern Laboratory Medicine, 2024, 39(5): 17-21, 29.
[4] 王希方,郑伟,马东瑞,等.ALKBH5调控GEFT的m6A修饰对胆管癌转移及EMT的实验研究[J].现代检验医学杂志, 2023, 38(4): 1-7,21. WANG X F, ZHENG W, MA D R, et al. Experimental study of GEFT m6A modification regulated by ALKBH5 on cholangiocarcinoma metastasis and EMT[J]. Journal of Modern Laboratory Medicine, 2023, 38(4): 1-7, 21.
[5] 张敏,邵棋.人乳腺珠蛋白、CXC趋化因子配体16和特异性周期蛋白在乳腺癌患者外周表达的临床意义[J].中国临床药理学杂志, 2022, 38(23): 2795-2798. ZHANG M, SHAO Q. Clinical significances of human mammaglobin, C-X-C motif chemokine ligand 16 and Cyclin D1 in the peripheral expression of breast cancer patients[J]. The Chinese Journal of Clinical Pharmacol-ogy, 2022, 38(23): 2795-2798.
[6] 方如旗,翁淑萍,陈霞平,等.MRI影像组学列线图术前预测子宫内膜癌淋巴结转移[J].中国医学影像学杂志,2023,31(11):1172-1177. FANG R Q, WENG S P, CHEN X P, et al. MRI radio-mics nomogram for preoperative prediction of lymph node metastasis in endometrial cancer[J]. Chinese Jour-nal of Medical Imaging, 2023, 31(11): 1172-1177.
[7] 张琴芬,常婧瑶,蔡云朗.人附睾蛋白4表达水平与子宫内膜癌淋巴结转移相关性的Meta分析[J].肿瘤防治研究,2022,49(9):944-951. ZHANG Q F, CHANG J Y, CAI Y L. Meta-analysis of relationship between expression level of human epi-didymis protein 4 and lymph node metastasis in endo-metrial cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 944-951.
[8] 薄娟,董江宁,陈玉兰,等.子宫内膜癌原发灶的ADC值联合纹理分析预测盆腔淋巴结转移的初步研究[J].临床放射学杂志, 2022, 41(7): 1313-1318. BO J, DONG J N, CHEN Y L, et al. The preliminary study of ADC value combined with texture analysis based on T2WI of endometrial cancer primary lesion to predict pelvic lymph node metastasis[J]. Journal of Clinical Radiology, 2022, 41(7): 1313-1318.
[9] LASKOV I, MICHAAN N, ZENG X, et al. The impact of intrauterine manipulators on outcome and recurrence patterns of endometrial cancer patients undergoing min-imally invasive surgery[J]. Journal of Women’s Health, 2024, 33(3): 355-363.
[10] 陈盼,张琳,金兰英,等.术前血浆纤维蛋白原联合中性粒细胞与淋巴细胞比值对子宫内膜癌手术患者预后的评估价值[J].中国实用妇科与产科杂志, 2023, 39(10): 1030-1034. CHEN P, ZHANG L, JIN L Y, et al. Predictive value of combined preoperative fibrinogen and neutrophil to lym-phocyte ratio for the prognosis of patients with endome-trial cancer after surgery[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2023, 39(10): 1030-1034.
[11] ZHU J R, QIU X Y, JIN X, et al. ZNF468-mediated epigenetic upregulation of VEGF-C facilitates lymph-angiogenesis and lymphatic metastasis in ESCC via PI3K/Akt and ERK1/2 signaling pathways[J]. Cellular Oncology, 2024, 47(5): 1927-1942.
[12] PANG X, LI T J, SHI R J, et al. IRF2BP2 drives lym-phatic metastasis in OSCC cells by elevating mitochon-drial fission-dependent fatty acid oxidation[J]. Molecu-lar Carcinogenesis, 2024, 63(1): 45-60.
[13] LU J, BANG H, KIM S M, et al. Retraction to: lymphatic me-tastasis-related TBL1XR1 enhances stemness and metastasis in gastric cancer stem-like cells by activating ERK1/2-SOX2 signaling (Oncogene), 2021, 40 (5): 922-936, 10.1038/s41388-020-01571-x) [J].Oncogene, 2024, 43(11):838.
[14] HARISA G I, SHERIF A Y, ALANAZI F K. Hybrid lymphatic drug delivery vehicles as a new avenue for targeted therapy: lymphatic trafficking, applications, challenges, and future horizons[J]. Journal of Mem-brane Biology, 2023, 256(3): 199-222.
[15] 傅立,毛友生.食管癌淋巴结转移与预后关系研究进展[J].中华胃肠外科杂志,2024,27(1):84-91. FU L, MAO Y S. Progress in correlation between lymph node metastasis and prognosis of esophageal cancer[J]. Chi-nese Journal of Gastrointestinal Surgery, 2024, 27(1): 84-91.
[16] 李玲玲,李赫,李舰,等.结合分子分型的子宫内膜癌患者淋巴结转移的危险因素分析[J].中华妇产科杂志,2023,58(10):733-741. LI L L, LI H, LI J, et al. Risk factor analysis of lymph node metastasis in endometrial carcinoma combined with molecular types[J]. Chinese Journal of Obstetrics and Gynecology, 2023, 58(10): 733-741.
[17] 张亚男,崔莹,王天娇,等.环状RNA_PLEKHM3通过miR-320/KLF4轴调控宫颈癌细胞上皮间质转化[J]. 安徽医科大学学报, 2024,59(3): 403-412. ZHANG Y N, CUI Y, WANG T J, et al. CircRNA_PLEKHM3 regulates epithelial mesenchymal transformation of cervical cancer cells through the miR-320/KLF4 axis[J]. Acta Universitatis Medicinalis Anhui, 2024, 59(3): 403-412.
[18] BRACKEN C P , GOODALL G J , GREGORY P A. RNA regulatory mechanisms controlling TGF-β sig-naling and EMT in cancer[J].Seminars in Cancer Biolo-gy, 2024, 102/103: 4-16.
[19] 杜书祥,赵英志,张雪涛,等.不同部位胃腺癌第12a组淋巴结转移的危险因素分析[J].中国癌症杂志, 2023, 33(6): 597-604. DU S X, ZHAO Y Z, ZHANG X T, et al. Analysis of group 12a lymph node metastasis at different sites of gastric adenocarcinoma and its risk factors[J]. China Oncology, 2023, 33(6): 597-604.
[20] 周瑜凝,姜文超,高晓东,等.1 096例早期胃癌淋巴结转移危险因素分析及列线图预测模型的构建[J].中华胃肠外科杂志,2024,27(7):711-717. ZHOU Y N, JIANG W C, GAO X D, et al. Analysis of risk factors for lymph node metastasis in 1 096 patients with early gastric cancer and establishment of a predic-tive nomogram[J]. Chinese Journal of Gastrointestinal Surgery, 2024, 27(7): 711-717.

相似文献/References:

[1]李 玲,罗雅文,何 霞,等.子宫内膜癌患者BMI与血清HE4,CA125联合检测的诊断价值[J].现代检验医学杂志,2018,33(05):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
　LI Ling,LUO Ya-wen,HE Xia,et al.Diagnostic Value of Combined Detection of Body Mass Index and Serum HE4,CA125 in Patients with Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(02):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
[2]李晓丽,胡陇娟.子宫内膜癌组织中长链非编码RNA ZEB1-AS1的表达与临床特征及对化疗药物耐药性研究[J].现代检验医学杂志,2019,34(04):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
　LI Xiao-li,HU Long-juan.Research on Expression and Clinical Characteristics of Long-Chain Non-Coding RNA ZEB1-AS1 in Endometrial Carcinoma and Resistance to Chemotherapy Drugs[J].Journal of Modern Laboratory Medicine,2019,34(02):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
[3]王娟,刘鑫,席稳燕.HMMR-AS1 在子宫内膜癌化疗耐药中的作用[J].现代检验医学杂志,2020,35(05):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
　WANG Juan,LIU Xin,XI Wen-yan.Effect of HMMR-AS1 on the Chemotherapy-Resistance of Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2020,35(02):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
[4]李功娟,张治洋,樊阳阳.FEZF1-AS1在子宫内膜癌中的表达及其与患者临床特征的相关性[J].现代检验医学杂志,2021,36(01):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
　LI Gong-juan,ZHANG Zhi-yang,FAN Yang-yang.Expression of FEZF1-AS1 in Endometrial Carcinoma and Its Correlation with Clinical Characteristics of Patients[J].Journal of Modern Laboratory Medicine,2021,36(02):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
[5]陈丽华,朱婕曼,刘玉凤,等.子宫内膜癌组织中血管紧张素~1-7及线粒体组装受体水平表达与临床病理特征的相关性[J].现代检验医学杂志,2021,36(02):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
　CHEN Li-hua,ZHU Jie-man,LIU Yu-feng,et al.Correlation between the Expression of Angiotensin (1-7) and Mitochondrial Assembled Receptors and Clinicopathological Characteristics in Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2021,36(02):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
[6]陈晓宇,曾庆维,陈红林,等.子宫内膜癌组织中miR-3188和mTOR表达量与预后的相关性研究[J].现代检验医学杂志,2021,36(06):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
　CHEN Xiao-yu,ZENG Qing-wei,CHEN Hong-lin,et al.Study on the Correlation between the Expression Levels of miR-3188 and mTOR in Endometrial Cancer and the Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(02):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
[7]刘静雅,张海亮,李宝平,等.长链非编码 RNA SNHG1在子宫内膜癌中的表达及调控 PI3K/AKT信号通路的研究[J].现代检验医学杂志,2022,37(01):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
　LIU Jing-ya,ZHANG Hai-liang,LI Bao-ping,et al.Expression of Long Non-coding RNA SNHG1 in Endometrial Carcinoma and Its Regulation of PI3K/AKT Signaling Pathway[J].Journal of Modern Laboratory Medicine,2022,37(02):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
[8]彭 浩,张印星,谢 环.长链非编码RNA CDKN2BAS 在子宫内膜癌组织表达及其生物学功能研究[J].现代检验医学杂志,2023,38(03):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
　PENG Hao,ZHANG Yin-xing,XIE Huan.Expression and Biological Function of Long Non-coding RNA CDKN2BAS in Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(02):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
[9]梁燕茹,郑 瑜,李 倩.子宫内膜癌患者术前血清apo AI 和Apelin 水平检测对预测淋巴脉管间隙浸润风险的价值研究[J].现代检验医学杂志,2023,38(05):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
　LIANG Yanru,ZHENG Yu,LI Qian.Value of Preoperative Serum Apo AI and Apelin Levels in Predicting the Risk of Lymph Node Vascular Space Infiltration in Patients with Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2023,38(02):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
[10]陆 瑞,郭红霞,吴苗苗,等.KIF18B 通过激活Wnt/β catenin 信号通路促进子宫内膜癌细胞增殖和转移的实验研究[J].现代检验医学杂志,2023,38(05):58.[doi:10.3969/j.issn.1671-7414.2023.05.011]
　LU Rui,GUO Hongxia,WU Miaomiao,et al.Experimental Study of KIF18B Promoting Endometrial Cancer Cell Proliferation and Metastasis by Activating Wnt/β-catenin Signaling Pathway[J].Journal of Modern Laboratory Medicine,2023,38(02):58.[doi:10.3969/j.issn.1671-7414.2023.05.011]

备注/Memo

备注/Memo:
基金项目：南通市卫生健康委员会课题（项目编号：QN2022020）；南通市自然科学基金和社会民生科技计划项目（项目编号：MSZ2023044）。
作者简介：秦佳睿（1996-），女，硕士研究生，住院医师，研究方向：妇科肿瘤。
通讯作者：郑艳莉（1967-），女，本科，主任医师，研究方向：妇科肿瘤，E-mail：gaoshan1189@sina.com。
更新日期/Last Update: 2026-03-15